A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Inclusion Criteria:

1. Voluntary to participate in the clinical study, subjects and their family membersagree to sign the informed consent form and follow all trial procedures.

2. Male or female subjects 18-70 years of age.

3. Subjects are diagnosed as recurrent or refractory solid tumors (soft tissue sarcoma,gastric cancer, pancreatic cancer and bladder cancer) with identified unresectableadvanced or metastatic tumors by radiology and histology or cytology, progressionafter the first line or above treatment, or intolerance to standard treatment.

4. At least one measurable lesion in accordance with RECIST 1.1, the long diameter ofnon-lymph node lesions ≥10mm (millimeter) according to CT (computerized tomography)scan-sectional image, or the short diameter of lymph node lesions ≥15mm; the longestaxis of the measurable lesion ≥10 mm in CT scan (CT scan layer ≤ 5mm); FDG PET (fluorodeoxyglucose -positron emission tomography) of the measurable lesion > 3 SUV (standardized uptake values).

5. Subjects with ROR2 positive tumor tissue: the percentage of ROR2 positive stainingcells in tumor cells detected by immunohistochemistry or RNA (Ribonucleic acid) insitu hybridization is ≥ 50%. The samples could be used within one year , otherwisethe sample will be re-collected for biopsy.

6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score is 0 to 1.

7. Expected survival will be ≥ 12 weeks.

8. The organ and hematopoietic functions must meet the following requirements:

• Hemoglobin (HGB)≥90 g/L (gram per litre), no blood transfusion within twoweeks;

• White blood cell count (WBC) ≥ 2.5×10^9/L;

• Absolute neutrophil count (ANC) ≥ 1.5×10^9/L;

• Platelet count (PLT) ≥ 80×10^9/L;

• Total bilirubin (TBIL) ≤ 3.0ng/dL or ≤ 5 ULN (Upper Limit of Normal);

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN;AST and ALT≤ 5×ULN in case the abnormal hepatic function is caused byhepatocellular carcinoma or liver metastasis from other tumors;

• Serum creatinine (Cr) ≤ 1.5×ULN; or creatinine clearance (CrCl) ≥ 50 mL/min (milliliter per minute);

9. Prothrombin time (PT): INR (International Normalized Ratio) <1.7 or prolonged, PTprolonged < 4 seconds from normal level;

10. Normal neurologic evaluation;

11. Sufficient venous access for venous intravenous blood collection and infusion, noother contraindications for blood cell separation;

12. Able to receive treatment and follow-up, including the treatment at the enrolledsite;

13. Female subjects of childbearing age must take acceptable measures to minimize thepossibility of pregnancy during the trial. The serum or urine pregnancy test must benegative prior to pre-treatment for female subjects of childbearing age;

Exclusion Criteria:

1. Pregnant or breastfeeding female subjects;

2. Active infection of hepatitis B, or active hepatitis C;

3. Infection with HIV/AIDS (Human Immunodeficiency Virus / Acquired ImmunodeficiencySyndrome);

4. Other active infection with clinical significance;

5. Previous diseases or concurrent diseases: Subjects diagnosed as serious autoimmune disease in long-term (over two months)requirement of systemic immunosuppressant (steroid), or as immune mediatedsymptomatic diseases including ulcerative colitis, Crohn's disease, rheumatoidarthritis, systemic lupus erythematosus (SLE), autoimmune vasculitis (e.g.,Wegener's granulomatosis);

6. Subjects with previous diagnosis as motor neuron disease;

7. Subjects with previous disease of toxic epidermal necrolysis;

8. Having any mental disorder that may affect the understanding of informed consent andrelevant questionnaires, including dementia, altered mental status;

9. Having serious uncontrollable disease judged in the study that may affect thesubjects receiving the study treatment;

10. Subjects with other active malignant tumors in the past five years including basalor squamous cell skin cancer, superficial bladder cancer or in situ breast cancerwho have been completely cured, and without any follow-up treatment are notincluded;

11. Current using of systemic steroid or steroid inhalant;

12. Have used of immunotherapy treatment in the past three months or PD-1 (Programmedcell death protein 1) antibody, PD-L1 (Programmed death-ligand 1) antibody, PD-L2antibody, CD137 (tumor necrosis factor receptor superfamily member 9, 4-1BB)antibody or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) antibody, or celltherapy.

13. Allergy to immunotherapy or relevant medications;

14. Meningeal metastasis or central nervous system metastasis in the last 6 months, withobvious underlying diseases of the central nervous system, and leaving obvioussymptoms;

15. Subjects with NYHA (New York Heart Association) heart failure grade ≥ 2 oruncontrollable hypertension by standard treatment and requiring special treatment,or with history of myocarditis, or occurrence of myocardial infarction within oneyear;

16. Previous organ transplantation or be ready for organ transplantation;

17. Pancreatic cancer with pancreatitis;

18. Active bleeding;

19. Subjects with pleural effusion or abdominal effusion that require clinical treatmentor intervention;

20. Being judged by investigators as inappropriate to participate in this study.